FDA Releases New Opioid Plan as Senators Stall Robert Califf’s Confirmation as Commissioner

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Robert Califf, the nominee to serve as the next FDA commissioner, and other FDA leaders called for a broad plan to reassess the agency’s approach to prescription opioid medications. The move comes as Senators block a vote on his confirmation for the top post.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.
Conor Hale
Conor Hale

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login